Norway, Feb. 26 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces it is presenting new and confirmatory in vivo data for its circVec-AAV expression platform. The in vivo results show, for the first time, up to 50-fold enhanced AAV-circVec expression in the eye compared to conventional mRNA-based AAVs. These results open ophthalmology as a promising avenue for development of circVec based gene therapy.Circio management will provide an overview of the new circVec results and a financial update in a live webcast at 10:00am CET, today, 26 February 2026. CTO Dr. Thomas B Hansen will present a summary of recently completed experiments testing AAV gene ther...